Status:
COMPLETED
A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI Study
Lead Sponsor:
Santen Pharmaceutical Co., Ltd.
Conditions:
Primary Open Angle Glaucoma or Ocular Hypertension
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
The purposes of this study are to investigate the effect of intraocular pressure lowering efficacy and safety of DE-117 ophthalmic solution in subjects with primary open-angle glaucoma or ocular hyper...
Eligibility Criteria
Inclusion
- Primary open angle glaucoma or ocular hypertension
Exclusion
- Patients at risk of progression of visual field loss
- Patients with severe visual field defect
- Patients with any diseases that preclude participation in this study for safety reasons
Key Trial Info
Start Date :
July 2 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 28 2017
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT02822742
Start Date
July 2 2016
End Date
April 28 2017
Last Update
November 20 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tokyo, Japan